Entry Instance

HTTP 200 OK
Allow: GET, PUT, PATCH, DELETE, HEAD, OPTIONS
Content-Type: application/json
Vary: Accept

{
    "id": 915540,
    "url": "https://info.mzalendo.com/api/v0.1/hansard/entries/915540/?format=api",
    "text_counter": 12,
    "type": "speech",
    "speaker_name": "Nominated, JP",
    "speaker_title": "Hon. David ole Sankok",
    "speaker": {
        "id": 13166,
        "legal_name": "David Ole Sankok",
        "slug": "david-ole-sankok"
    },
    "content": " Thank you very much, Hon. Speaker. I, the undersigned, on behalf of Hemophilia Patients of Kenya, draw the attention of the House to the following: THAT, the right to health is a fundamental human right guaranteed in the Constitution of Kenya, with Article 43(1)(a) stipulating that every person has the right to the highest attainable standard of health, including the right to health care services; THAT, patients with hemophilia suffer substantially reduced quality of life on account of frequent bleeding episodes and disorders, most of which are life-threatening or lead to disabling joint disease (arthropathy) and shortened life expectancy; THAT, methods of treatment and management of hemophilia are costly and typically time-consuming, and thus end up placing a considerable burden on patients' physical, financial and psychological well-being; THAT, currently, the only treatment product recognised by the Ministry of Health in its Essential Drugs List is blood components, which means that the Kenya Medical Services Authority (KEMSA) cannot purchase the appropriate drugs to be used locally and even pharmaceuticals dealing in clotting factor concentrates cannot conveniently import the medicine into the country; THAT, the prevalence of hemophilia is one in every 10,000 individuals and, out of the approximately 4,500 hemophilia patients in Kenya, only 740 patients (or 16 per cent of the total) have been identified, hence the need for sustained awareness of the condition; THAT, the clotting factor concentrate donations received at present are insufficient and inconsistent, giving 30 per cent factor level for the 740 (16 per cent) patients that have so far been identified and diagnosed and thus, at times, forcing patients to revert to blood related products that require hospital admissions for transfusion; THEREFORE, your humble petitioners pray that the National Assembly, through the Departmental Committee on Health; (i) Recommends the recognition of clotting factor concentrates as part of hemophilia’s treatment and facilitates their availability in the Kenyan market; (ii) Recommends to the Ministry of Health the establishment of more treatment centres, the improvement of diagnostic capacity, the facilitation of training of health care service providers, the review of medical-training curriculum to include hemophilia and other bleeding disorders' The electronic version of the Official Hansard Report is for information purposes only. Acertified version of this Report can be obtained from the Hansard Editor."
}